Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Keranen, Susana Rosello
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer	Active, not recruiting	2	70	Europe	Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen	Inspirna, Inc.	Colorectal Cancer, Metastatic Colon Cancer	09/25	12/26
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer	Active, not recruiting	2	154	Europe, Canada, Japan, US, RoW	Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A	GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd	Neoplasms, Rectal	11/26	10/29
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors	Active, not recruiting	1/2	115	Europe, Canada, US	GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab	Nouscom SRL, Merck Sharp & Dohme LLC	Solid Tumor, Adult	04/25	11/26